MA31442B1 - 3-(imidazolyl)-pyrazolo [3,4-b]pyridines - Google Patents

3-(imidazolyl)-pyrazolo [3,4-b]pyridines

Info

Publication number
MA31442B1
MA31442B1 MA32416A MA32416A MA31442B1 MA 31442 B1 MA31442 B1 MA 31442B1 MA 32416 A MA32416 A MA 32416A MA 32416 A MA32416 A MA 32416A MA 31442 B1 MA31442 B1 MA 31442B1
Authority
MA
Morocco
Prior art keywords
pyrazolo
imidazolyl
ccr1
compounds
pyridines
Prior art date
Application number
MA32416A
Other languages
English (en)
Inventor
Lianfa Li
Andrew M K Pennell
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MA31442B1 publication Critical patent/MA31442B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS QUI AGISSENT COMME DE PUISSANTS ANTAGONISTES DU RÉCEPTEUR CCR1 ET QUI PRÉSENTENT UNE ACTIVITÉ ANTI-INFLAMMATOIRE IN VIVO. LES COMPOSÉS SONT DES DÉRIVÉS DE 3-IMIDAZOLYL-PYRAZOLO[3,4-B]PYRIDINE ET SONT UTILES DANS DES COMPOSITIONS PHARMACEUTIQUES, DES PROCÉDÉS DE TRAITEMENT DE MALADIES MÉDIÉES PAR LE CCR1, ET COMME CONTRÔLES DANS DES TESTS POUR L'IDENTIFICATION D'ANTAGONISTES COMPÉTITIFS DU CCR1.
MA32416A 2007-05-22 2009-12-14 3-(imidazolyl)-pyrazolo [3,4-b]pyridines MA31442B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93294807P 2007-05-22 2007-05-22

Publications (1)

Publication Number Publication Date
MA31442B1 true MA31442B1 (fr) 2010-06-01

Family

ID=40075474

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32416A MA31442B1 (fr) 2007-05-22 2009-12-14 3-(imidazolyl)-pyrazolo [3,4-b]pyridines

Country Status (27)

Country Link
US (4) US7629344B2 (fr)
EP (1) EP2155712B1 (fr)
JP (1) JP5457338B2 (fr)
KR (1) KR101534661B1 (fr)
CN (1) CN101743238B (fr)
AR (2) AR066701A1 (fr)
AU (1) AU2008256862B2 (fr)
BR (1) BRPI0811849A8 (fr)
CA (1) CA2687625C (fr)
CL (1) CL2008001493A1 (fr)
CO (1) CO6241152A2 (fr)
DK (1) DK2155712T3 (fr)
EA (1) EA015529B1 (fr)
ES (1) ES2600477T3 (fr)
HK (1) HK1141524A1 (fr)
HU (1) HUE032273T2 (fr)
IL (1) IL202248A (fr)
JO (1) JO3319B1 (fr)
MA (1) MA31442B1 (fr)
MX (1) MX2009012567A (fr)
NZ (1) NZ581405A (fr)
PE (1) PE20090293A1 (fr)
PL (1) PL2155712T3 (fr)
PT (1) PT2155712T (fr)
TW (1) TWI418353B (fr)
UA (1) UA99619C2 (fr)
WO (1) WO2008147815A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7777035B2 (en) * 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
KR20150081370A (ko) 2006-07-10 2015-07-13 파이온 유케이 리미티드 속효형 벤조디아제핀 염 및 이의 중합체 형태
EA015529B1 (ru) * 2007-05-22 2011-08-30 Кемосентрикс, Инк. 3-(имидазолил)пиразоло[3,4-b]пиридины
US8343975B2 (en) * 2008-09-11 2013-01-01 Penglie Zhang 4-amino-3-(imidazolyl)-pyrazolo[3,4-D]pyrimidines
EP2305647A1 (fr) * 2009-09-18 2011-04-06 PAION UK Limited Procédé de préparation d'ester de méthyle d'acide 3-[(4S)-8-bromo-1-méthyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1,4]benzodiazépine-4-yl] propionique ou son sulfonate de benzène, et composants utiles dans ce procédé
EP2450039A1 (fr) 2010-11-08 2012-05-09 PAION UK Ltd. Régime de dosage permettant la sédation avec CNS 7056 (Remimazolam)
MX367436B (es) * 2012-08-27 2019-08-21 Chemocentryx Inc Antagonistas de los receptores de quimiocina.
WO2014089495A1 (fr) 2012-12-07 2014-06-12 Chemocentryx, Inc. Lactames de diazole
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
US20170195506A1 (en) * 2015-12-30 2017-07-06 Kabushiki Kaisha Toshiba Image forming apparatus forming location free print system and print job retrieval method by the same
JP7539231B2 (ja) * 2016-04-07 2024-08-23 ケモセントリクス，インコーポレーテッド Ｐｄ－１阻害剤又はｐｄ－ｌ１阻害剤と組み合わせてｃｃｒ１アンタゴニストを投与することによる腫瘍負荷の低減
US11872217B2 (en) 2019-07-10 2024-01-16 Chemocentryx, Inc. Indanes as PD-L1 inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US715746A (en) * 1902-02-25 1902-12-16 Nat Tube Co Apparatus for handling tube-plates.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
DE2862079D1 (en) * 1977-10-26 1982-12-09 Wellcome Found Imidazoline derivatives and salts thereof, their synthesis, pesticidal formulations containing the imidazolines, preparation thereof and their use as pesticides
AU518569B2 (en) 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4927942A (en) 1988-12-15 1990-05-22 Texaco Chemical Co. Method for the preparation of imidazoles
WO1990013332A1 (fr) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Support pour medicaments a liberation progressive
EP0470246B1 (fr) 1990-02-28 1995-06-28 Medtronic, Inc. Prothese pour l'elution intraluminale d'un medicament
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US5833651A (en) 1996-11-08 1998-11-10 Medtronic, Inc. Therapeutic intraluminal stents
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
JP4723242B2 (ja) 2002-06-12 2011-07-13 ケモセントリックス インコーポレーティッド 炎症および免疫障害治療用ｃｃｒ１アンタゴニストとして使用するための１−アリール−４−置換ピペラジン誘導体
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
CA2558211C (fr) 2004-03-03 2013-09-03 Chemocentryx, Inc. Heterocycles d'azote bicycliques et pontes
KR101418024B1 (ko) 2005-06-22 2014-07-16 케모센트릭스, 인크. 아자인다졸 화합물 및 사용방법
US7777035B2 (en) * 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
KR200434921Y1 (ko) * 2006-07-10 2007-01-02 서용석 야외용 간이 화장실
EA015529B1 (ru) * 2007-05-22 2011-08-30 Кемосентрикс, Инк. 3-(имидазолил)пиразоло[3,4-b]пиридины

Also Published As

Publication number Publication date
US20080300257A1 (en) 2008-12-04
AU2008256862B2 (en) 2013-01-31
EP2155712A1 (fr) 2010-02-24
BRPI0811849A8 (pt) 2019-01-15
EA200901572A1 (ru) 2010-04-30
IL202248A (en) 2015-04-30
UA99619C2 (en) 2012-09-10
IL202248A0 (en) 2010-06-16
TWI418353B (zh) 2013-12-11
WO2008147815A1 (fr) 2008-12-04
US20100173911A1 (en) 2010-07-08
JP5457338B2 (ja) 2014-04-02
AR110128A2 (es) 2019-02-27
AU2008256862A8 (en) 2009-12-24
TW200906402A (en) 2009-02-16
JP2010528038A (ja) 2010-08-19
CA2687625C (fr) 2015-12-22
CO6241152A2 (es) 2011-01-20
PE20090293A1 (es) 2009-04-04
ES2600477T3 (es) 2017-02-09
US20130184289A1 (en) 2013-07-18
US7960388B2 (en) 2011-06-14
US7629344B2 (en) 2009-12-08
CN101743238B (zh) 2014-04-30
US20120010214A1 (en) 2012-01-12
US8481545B2 (en) 2013-07-09
PL2155712T3 (pl) 2017-02-28
PT2155712T (pt) 2016-12-13
HK1141524A1 (zh) 2010-11-12
EP2155712B1 (fr) 2016-09-07
AR066701A1 (es) 2009-09-09
KR101534661B1 (ko) 2015-07-09
KR20100022998A (ko) 2010-03-03
EP2155712A4 (fr) 2011-05-11
HUE032273T2 (en) 2017-09-28
AU2008256862A1 (en) 2008-12-04
JO3319B1 (ar) 2019-03-13
CN101743238A (zh) 2010-06-16
NZ581405A (en) 2011-06-30
CA2687625A1 (fr) 2008-12-04
CL2008001493A1 (es) 2008-08-29
DK2155712T3 (en) 2016-12-19
EA015529B1 (ru) 2011-08-30
MX2009012567A (es) 2010-02-17
BRPI0811849A2 (pt) 2014-11-18

Similar Documents

Publication Publication Date Title
MA31442B1 (fr) 3-(imidazolyl)-pyrazolo [3,4-b]pyridines
MA29568B1 (fr) Composes d'azaindazole et methodes d'utilisation desdits composes
TN2009000524A1 (en) Novel dicarboxylic acid derivatives as s1p1 receptor agonists
ATE424402T1 (de) Imidazopyridinverbindungen
MA31470B1 (fr) Dérivés de pipéridine utiles comme antagonistes vis-à-vis des récepteurs de l'orexine
HK1098460A1 (en) Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
GEP20084552B (en) Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands
MA31290B1 (fr) Derives d'amino-pyridine comme agonistes du recepteur s1p1/edg1
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
TW200613305A (en) Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
MA30631B1 (fr) Inhibiteurs de tyrosine kinase
IL174678A0 (en) Arylindenophyridines and arylindenophyrimidines and their use as adenosine a2a receptor antagonist
TW200624432A (en) Imidazo [1,2-a] pyridine compounds, compositions, uses and methods related thereto
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
MA29643B1 (fr) Benzocycloheptapyridines comme inhibiteurs du recepteur tyrozine kinase met
CR9622A (es) Derivados de pirazolo[3,4-d]azepina como antagonistas de histamina h3
MA29561B1 (fr) DERIVES DE PYRIDO[2,3-d] PYRIMIDINE, LEUR PREPARATION, LEUR APPLICATION EN THERAPEUTIQUE
BR0215699A (pt) Derivados 5-oxo e 5-tio de 5h-indeno'1,2-bipiridina com receptor a2a de adenosina ligante e fosfodiesterase inibindo atividade para o tratamento de desordens neurodegenerativas e doenças relacionadas a inflamação
MX2007000576A (es) Agonistas del receptor nicotinico para el tratamiento de enfermedades inflamatorias.
MA29910B1 (fr) Potentialisateurs des recepteurs ampa
WO2006018708A3 (fr) Derives de pyrrolidine utilises en tant qu'antagonistes des recepteurs muscariniques
US20220194940A1 (en) Heterocyclic inhibitors of tyrosine kinase
EP1883624A4 (fr) Derives de carbamate de d-homoandrosta-17-yl comme ligands recepteurs de glucocorticoide selectif
DE602004018844D1 (de) Als antagonisten des muscarinrezeptors geeignete xanthinderivate